CJC/IPA

CJC/IPA

≥99% Purity, HLPC.

Aliquot injectable vials fully sterilized

Shipped as Lyophilized Powder

CJC-1295 (Mod GRF 1-29) and Ipamorelin

CJC-1295 (Mod GRF 1-29):
A modified Growth Hormone–Releasing Hormone (GHRH) analog composed of the first 29 amino acids of endogenous GHRH, engineered for enhanced stability and biological activity through amino acid substitutions (commonly referred to as Mod GRF 1-29). Unlike the DAC version, this form lacks the Drug Affinity Complex, resulting in a shorter half-life (≈30 minutes) and a more physiologic GH release pattern. It acts directly on the GHRH receptor in the anterior pituitary to stimulate natural, pulsatile secretion of growth hormone (GH).
This pulsatility maintains receptor sensitivity and promotes IGF-1 elevation, leading to increased protein synthesis, lipid metabolism, and tissue regeneration. The shorter duration of action allows for precise control of GH release cycles, often used to mimic or augment endogenous GH rhythms, particularly when combined with a GHRP such as Ipamorelin.

Ipamorelin:
A selective Growth Hormone Secretagogue (GHS) and ghrelin receptor (GHSR-1a) agonist, Ipamorelin stimulates GH release through a pathway independent of GHRH, acting synergistically rather than competitively. It elicits potent GH secretion without significant elevation of cortisol, prolactin, or ACTH, differentiating it from earlier GHRPs like GHRP-6.
Ipamorelin’s mechanism supports muscle anabolism, fat reduction, and cellular repair, while improving sleep quality and recovery efficiency via GH-mediated anabolic and restorative processes.

Synergistic Mechanisms

When administered together, CJC-1295 (Mod GRF 1-29) and Ipamorelin create a potent, yet physiologically balanced, enhancement of endogenous growth hormone secretion:

• Dual-pathway stimulation:
  CJC-1295 (Mod GRF 1-29) activates the GHRH receptor, while Ipamorelin targets the ghrelin receptor, leading to amplified GH release from multiple signaling cascades within somatotrophs. 
• Physiologic pulsatility:
  The short half-life of Mod GRF 1-29 aligns GH pulses closely with the body’s circadian rhythm, while Ipamorelin extends the amplitude and duration of each pulse—maintaining natural secretion dynamics without receptor desensitization. 
• Enhanced IGF-1 synthesis:
  The combined effect increases hepatic IGF-1 output, promoting collagen formation, muscle hypertrophy, lipolysis, and connective tissue regeneration. 

Anabolic recovery and tissue repair:
Together, the peptides support accelerated healing of musculoskeletal and soft tissue injuries, improved sleep-dependent repair, and enhanced metabolic balance—making the pairing valuable for regenerative and performance optimization protocols.